UNSPSC 51314332: Chlorpheniramine/guaifenesin/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314332 Chlorpheniramine/guaifenesin/phenylpropanolamine is a Commodity code that captures state and local procurement of specific branded and generic pharmaceutical formulations, though recent opportunities show the code tagged to broader pharmacy benefit procurement and emergency medical supply sourcing rather than this particular combination product. State and local governments use this code to solicit manufacturing and supply agreements for pharmaceutical products through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The Minnesota Department of Administration's Office of State Procurement administers MMCAP, which serves participating state and local government facilities across multiple states including Oregon.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, response deadline July 26, 2023. The Texas Health and Human Services Commission issued Request for Information HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, with response deadline April 3, 2026. MMCAP released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products to be supplied through three authorized wholesalers (AmerisourceBergen/Cencara, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. Vendors must meet cGMP and Drug Supply Chain Security Act certification, maintain relationships with at least two of the three authorized wholesalers, and comply with $5 million commercial general liability and $2 million professional liability insurance minimums. MMCAP weights price competitiveness at 75 percent of evaluation and retains the right to make sole, dual, or multi-awards based on therapeutic and patient safety considerations.